EP0650370A4 - Methods and compositions for targeting specific tissue. - Google Patents
Methods and compositions for targeting specific tissue.Info
- Publication number
- EP0650370A4 EP0650370A4 EP93914334A EP93914334A EP0650370A4 EP 0650370 A4 EP0650370 A4 EP 0650370A4 EP 93914334 A EP93914334 A EP 93914334A EP 93914334 A EP93914334 A EP 93914334A EP 0650370 A4 EP0650370 A4 EP 0650370A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- specific tissue
- targeting specific
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90609292A | 1992-06-08 | 1992-06-08 | |
US906092 | 1992-06-08 | ||
PCT/US1993/005260 WO1993025234A1 (en) | 1992-06-08 | 1993-06-03 | Methods and compositions for targeting specific tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0650370A1 EP0650370A1 (en) | 1995-05-03 |
EP0650370A4 true EP0650370A4 (en) | 1995-11-22 |
Family
ID=25421920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93914334A Withdrawn EP0650370A4 (en) | 1992-06-08 | 1993-06-03 | Methods and compositions for targeting specific tissue. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0650370A4 (en) |
JP (1) | JPH07507689A (en) |
WO (1) | WO1993025234A1 (en) |
Families Citing this family (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0746625B1 (en) * | 1992-11-09 | 2004-03-31 | THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targetable vector particles |
GB9402857D0 (en) | 1994-02-15 | 1994-04-06 | Isis Innovation | Targeting gene therapy |
US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
EP0840797B1 (en) * | 1995-07-25 | 2014-09-03 | Crucell Holland B.V. | Methods and means for targeted gene delivery |
GB9519776D0 (en) * | 1995-09-28 | 1995-11-29 | Casimir Colin | Materials and methods relating to the transfer of nucleic acid into stem cells |
EP0880596A1 (en) * | 1995-12-28 | 1998-12-02 | Chiron Corporation | Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells |
DE19605279A1 (en) | 1996-02-13 | 1997-08-14 | Hoechst Ag | Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use |
CA2266656A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
CA2285937C (en) | 1997-04-10 | 2010-12-14 | Frederick L. Hall | Modified proteins which bind extracellular matrix components |
US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
WO1998055611A1 (en) * | 1997-06-06 | 1998-12-10 | Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
DE69838584T2 (en) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE |
DE69838483T2 (en) | 1997-10-14 | 2008-07-03 | Darwin Molecular Corp. | THYMIDINKINASE MUTANES AND FUSION PROTEINS WITH THYMIDINE KINASE AND GUANYLATEKINASE ACTIVITIES |
CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
EP2278011A3 (en) | 1998-01-14 | 2012-03-07 | Novartis Vaccines and Diagnostics S.r.l. | Neisseria meningitidis antigens |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
AU761780B2 (en) | 1998-05-01 | 2003-06-12 | Glaxosmithkline Biologicals Sa | Neisseria meningitidis antigens and compositions |
EP0959135A1 (en) * | 1998-05-20 | 1999-11-24 | Introgene B.V. | Display of viral proteins and targeted delivery to cellular receptor |
EP0972841A1 (en) * | 1998-05-20 | 2000-01-19 | Introgene B.V. | Display of viral proteins as ligands for cell-surface receptor |
EP0959136A1 (en) * | 1998-05-20 | 1999-11-24 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
EP0960942A3 (en) * | 1998-05-20 | 2000-01-12 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
JP2002527066A (en) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | Metastatic breast and colon cancer regulatory genes |
CA2352532C (en) | 1998-11-27 | 2014-10-14 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
PT1141331E (en) | 1998-12-16 | 2008-12-22 | Novartis Vaccines & Diagnostic | Human cyclin-dependent kinase (hpnqalre) |
US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
JP2002533124A (en) | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Improved expression of HIV polypeptide and generation of virus-like particles |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6911429B2 (en) | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
US7396905B1 (en) | 1999-05-21 | 2008-07-08 | Mckeon Frank | Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
AU784203B2 (en) | 1999-10-29 | 2006-02-23 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
PT1232264E (en) | 1999-11-18 | 2009-11-26 | Novartis Vaccines & Diagnostic | Human fgf-21 gene and gene expression products |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
EP1854476A3 (en) | 2000-02-09 | 2008-05-07 | Bas Medical, Inc. | Use of relaxin to treat diseases related to vasoconstriction |
JP2003531583A (en) | 2000-03-08 | 2003-10-28 | カイロン コーポレイション | Human FGF-23 gene and gene expression product |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
PT1370684E (en) | 2000-06-15 | 2008-09-08 | Novartis Vaccines & Diagnostic | Polynucleotides related to colon cancer |
MX357775B (en) | 2000-10-27 | 2018-07-20 | J Craig Venter Inst Inc | Nucleic acids and proteins from streptococcus groups a b. |
CA2430379A1 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
JP2004525620A (en) | 2001-01-17 | 2004-08-26 | トルビオン・ファーマシューティカルズ・インコーポレイテッド | Binding domain-immunoglobulin fusion protein |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
AU2002255995A1 (en) | 2001-03-30 | 2002-10-15 | Avigenics, Inc. | Avian lysozyme promoter |
US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
WO2002081639A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
WO2002090600A2 (en) | 2001-05-08 | 2002-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
CA2452119C (en) | 2001-07-05 | 2013-10-15 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
MXPA04003852A (en) | 2001-10-26 | 2005-02-17 | Univ Tennessee Res Foundation | Multivalent streptococcal vaccine compositions and methods for use. |
CN100398551C (en) | 2001-11-09 | 2008-07-02 | 乔治敦大学 | Novel isoforms of vascular endothelial cell growth inhibitor |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
ATE406912T1 (en) | 2001-12-12 | 2008-09-15 | Novartis Vaccines & Diagnostic | IMMUNIZATION AGAINST CHLAMYDIA TRACHEOMATIS |
JP4376629B2 (en) | 2002-01-08 | 2009-12-02 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Gene products differentially expressed in cancerous breast cells and methods of use thereof |
US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
CA2479118A1 (en) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
US20040023267A1 (en) | 2002-03-21 | 2004-02-05 | Morris David W. | Novel compositions and methods in cancer |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
CN102746399B (en) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | Anti-ngf antibodies and using method thereof |
JP2007524362A (en) | 2003-02-14 | 2007-08-30 | サイグレス ディスカバリー, インコーポレイテッド | Therapeutic GPCR targets in cancer |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
AU2004213044A1 (en) | 2003-02-19 | 2004-09-02 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
US8052966B2 (en) | 2003-04-21 | 2011-11-08 | University Of Southern California | Methods and compositions for treating metastatic cancer |
US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
CN1947012A (en) | 2003-12-23 | 2007-04-11 | 瑞纳神经科学公司 | Agonist anti-trkC antibodies and methods using same |
US8268324B2 (en) | 2004-03-29 | 2012-09-18 | Galpharma Co., Ltd. | Modified galectin 9 proteins and use thereof |
SI1732949T1 (en) | 2004-04-07 | 2010-05-31 | Rinat Neuroscience Corp | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
US7875275B2 (en) | 2004-06-16 | 2011-01-25 | The General Hospital Corporation | Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes |
US8865171B2 (en) | 2004-07-09 | 2014-10-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of Hendra and Nipah virus G glycoprotein |
AU2005275062A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utah Research Foundation | Netrin-related compositions and uses |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
CN101180312A (en) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | Immunogens from uropathogenic escherichia coli |
CA2604885A1 (en) | 2005-04-07 | 2006-10-19 | Guoying Yu | Cacna1e in cancer diagnosis, detection and treatment |
AU2006235258A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
CA2615615A1 (en) | 2005-07-22 | 2007-02-01 | Y's Therapeutics Co., Ltd. | Anti-cd26 antibodies and methods of use thereof |
HUE026303T2 (en) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-cell reduction using CD37-specific and CD20-specific binding molecules |
CN101309704B (en) | 2005-11-14 | 2012-10-10 | 礼纳特神经系统科学公司 | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
JP2009525319A (en) | 2006-02-02 | 2009-07-09 | ライナット ニューロサイエンス コーポレイション | Method of treating obesity by administering a trkB antagonist |
EP1993558B1 (en) | 2006-02-27 | 2014-07-30 | The Regents of The University of California | Oxysterol compounds and the hedgehog pathway |
BRPI0712850A8 (en) | 2006-06-07 | 2018-05-02 | Bioalliance Cv | antibodies that recognize a cd-43 and cea carbohydrate-containing epitope expressed in cancer cells and methods of using them |
DK2054431T3 (en) | 2006-06-09 | 2012-01-02 | Novartis Ag | Conformers of bacterial adhesins |
EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
US20100166788A1 (en) | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
PT2468300T (en) | 2006-09-26 | 2018-01-30 | Infectious Disease Res Inst | Vaccine composition containing synthetic adjuvant |
EP2111553B1 (en) | 2007-01-24 | 2018-09-19 | Carnegie Mellon University | Optical biosensors |
EP2139447A2 (en) | 2007-03-20 | 2010-01-06 | Harold Brem | Gm-csf cosmeceutical compositions and methods of use thereof |
AP2009005028A0 (en) | 2007-04-10 | 2009-12-31 | Univ Tulane | Soluble and membrane-anchored forms of lassa virussubunit proteins |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
CA2707663C (en) | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
AU2008337100B2 (en) | 2007-12-17 | 2013-02-28 | Pfizer Limited | Treatment of interstitial cystitis |
RU2528738C2 (en) | 2007-12-18 | 2014-09-20 | Биоэллаенс К.В. | Antibodies recognising epitope on cd43 and cea expressed on malignant cells and methods for using them |
WO2009126306A2 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
DK2132228T3 (en) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37 immunotherapeutic agent and combination with its bifunctional chemotherapeutic agent |
US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
TWI445716B (en) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9 antagonists |
CN102224254A (en) | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4 and uses thereof |
US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
EP2379720B1 (en) | 2009-01-20 | 2016-08-17 | Alona Zilberberg | Mir-21 promoter driven targeted cancer therapy |
US9719069B2 (en) | 2009-01-27 | 2017-08-01 | University Of Utah Research Foundation | Methods and compositions relating to viral latency |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
EP2403526B1 (en) | 2009-03-06 | 2019-05-15 | GlaxoSmithKline Biologicals SA | Chlamydia antigens |
SG174426A1 (en) | 2009-03-20 | 2011-10-28 | Angioblast Systems Inc | Production of reprogrammed pluripotent cells |
US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
JP5802195B2 (en) | 2009-04-27 | 2015-10-28 | オタワ ホスピタル リサーチ インスティチュート | Compositions and methods for modulating stem cells and uses thereof |
DK2437753T3 (en) | 2009-06-05 | 2016-12-19 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
DK2464658T3 (en) | 2009-07-16 | 2014-12-15 | Novartis Ag | Detoxified escherichia coli immunogens |
WO2011038063A1 (en) | 2009-09-28 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Method of diagnosing and treating interstitial cystitis |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
US20130040853A1 (en) | 2010-01-21 | 2013-02-14 | Dana-Farber Cancer Institute Inc. | Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation |
AR080291A1 (en) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
US8747844B2 (en) | 2010-07-30 | 2014-06-10 | Saint Louis University | Methods of treating pain |
US9539427B2 (en) | 2010-11-08 | 2017-01-10 | The Johns Hopkins University | Methods for improving heart function |
US9198975B2 (en) | 2010-12-01 | 2015-12-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeting sites of neovascular growth |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
AU2011352228B2 (en) | 2010-12-27 | 2015-12-03 | Brown University | Therapeutic and diagnostic methods involving biglycan and utrophin |
CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
WO2013028527A1 (en) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions and methods for treating cancer |
US8969519B2 (en) | 2011-09-13 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
JP5936702B2 (en) | 2011-11-11 | 2016-06-22 | ライナット ニューロサイエンス コーポレイション | Antibodies specific for TROP-2 and uses thereof |
SG11201402828XA (en) | 2011-12-22 | 2014-10-30 | Rinat Neuroscience Corp | Human growth hormone receptor antagonist antibodies and methods of use thereof |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
KR20200075023A (en) | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | Prostate-associated antigens and vaccine-based immunotherapy regimens |
JP6262723B2 (en) | 2012-05-07 | 2018-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | Oxysterol analog OXY133 induces bone development and hedgehog signaling and inhibits adipogenesis |
EP2850431B1 (en) | 2012-05-16 | 2018-04-18 | Immune Design Corp. | Vaccines for hsv-2 |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
EP2917237A1 (en) | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
AU2014236208B2 (en) | 2013-03-14 | 2018-07-19 | Genvivo, Inc. | Thymidine kinase diagnostic assay for gene therapy applications |
EP2970502A4 (en) | 2013-03-15 | 2016-11-30 | Dyax Corp | Anti-plasma kallikrein antibodies |
CA2909221A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
CA2911205A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
US9248189B2 (en) | 2013-05-07 | 2016-02-02 | Pfizer Inc. | Anti-glucagon receptor antibodies and pharmaceutical compositions thereof |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
EP3008043A2 (en) | 2013-06-14 | 2016-04-20 | University Of Utah Research Foundation | Triazol-1-ol analogs anti-retroviral latency drugs |
WO2015006641A2 (en) | 2013-07-12 | 2015-01-15 | Georgia State University Research Foundation, Inc. | Methods and compositions for interference with dna polymerase and dna synthesis |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
BR112016002008B1 (en) | 2013-08-02 | 2021-06-22 | Pfizer Inc. | ANTI-CXCR4 ANTIBODIES, THEIR USE, ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL COMPOSITION |
CN105814081B (en) | 2013-11-13 | 2021-02-02 | 辉瑞大药厂 | Tumor necrosis factor-like ligand 1A specific antibody, and composition and application thereof |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US11624093B2 (en) | 2014-04-24 | 2023-04-11 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
AU2015259465A1 (en) | 2014-05-13 | 2016-11-17 | Bioatla Llc | Conditionally active biological proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
KR102615681B1 (en) | 2014-08-28 | 2023-12-18 | 바이오아트라, 인코퍼레이티드 | Conditionally active chimeric antigen receptors for modified t-cells |
BR112017004131A2 (en) | 2014-09-03 | 2017-12-12 | Bioatla Llc | method of producing a conditionally active biological protein, conditionally active biological protein, chimeric antigen receptor, and cytotoxic cell. |
AU2015315199B2 (en) | 2014-09-09 | 2020-02-27 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
CA2963602A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
AU2016229238B2 (en) | 2015-03-06 | 2022-06-02 | Dana-Farber Cancer Institute, Inc. | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers |
ES2805206T3 (en) | 2015-03-10 | 2021-02-11 | Univ Massachusetts | GDF6 and BMP signaling approach for melanoma therapy |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
JP6913025B2 (en) | 2015-04-13 | 2021-08-04 | ファイザー・インク | Therapeutic antibodies and their use |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
IL257047B1 (en) | 2015-07-21 | 2024-07-01 | Dyax Corp | A monoclonal antibody inhibitor of factor xiia |
EP3325010B1 (en) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antibodies to coagulation factor xia and uses thereof |
IL302353A (en) | 2015-08-19 | 2023-06-01 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
KR20230155021A (en) | 2015-09-15 | 2023-11-09 | 스칼러 락, 인크. | Anti-pro/latent-myostatin antibodies and uses thereof |
CN108367004B (en) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | CD3 binding polypeptides |
IL300420B1 (en) | 2015-10-16 | 2024-05-01 | Univ Columbia | Compositions and methods for inhibition of lineage specific antigens |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
CA2946113A1 (en) | 2015-10-23 | 2017-04-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
CN106699889A (en) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | PD-1 resisting antibody and treatment application thereof |
CN108712911A (en) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | Antibody and its conjugate |
US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
KR20190080825A (en) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-cell dysfunction state-specific gene expression regulators and their uses |
US11254742B2 (en) | 2016-05-13 | 2022-02-22 | Bioatla, Inc. | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
IL299285A (en) | 2016-05-16 | 2023-02-01 | Access To Advanced Health Inst | Formulation containing tlr agonist and methods of use |
AU2017273650B2 (en) | 2016-06-01 | 2022-08-18 | Access To Advanced Health Institute | Nanoalum particles containing a sizing agent |
US20180030478A1 (en) | 2016-07-01 | 2018-02-01 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
WO2018057618A1 (en) | 2016-09-20 | 2018-03-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators |
US20180119141A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
WO2018148246A1 (en) | 2017-02-07 | 2018-08-16 | Massachusetts Institute Of Technology | Methods and compositions for rna-guided genetic circuits |
BR112019017500A2 (en) | 2017-03-03 | 2020-04-14 | Rinat Neuroscience Corp | anti-gitr antibodies and methods of using them |
CA3056182A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
WO2018191548A2 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
TWI757499B (en) | 2017-06-02 | 2022-03-11 | 美商輝瑞大藥廠 | Antibodies specific for flt3 and their uses |
EP3634496A4 (en) | 2017-06-06 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
US11430545B2 (en) | 2017-06-13 | 2022-08-30 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anti-nucleolin antibody |
US11970707B2 (en) | 2017-09-18 | 2024-04-30 | Children's Hospital Medical Center | Strong insulator and uses thereof in gene delivery |
EP3692370A2 (en) | 2017-10-04 | 2020-08-12 | OPKO Pharmaceuticals, LLC | Articles and methods directed to personalized therapy of cancer |
CA3090032A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Antibodies specific for cd70 and their uses |
MX2020008184A (en) | 2018-02-01 | 2020-09-22 | Pfizer | Chimeric antigen receptors targeting cd70. |
BR112020016859A2 (en) | 2018-02-28 | 2020-12-29 | Pfizer Inc. | IL-15 VARIANTS AND USES OF THE SAME |
BR112020022897A2 (en) | 2018-05-23 | 2021-02-23 | Pfizer Inc. | specific antibodies to cd3 and their uses |
BR112020022595A2 (en) | 2018-05-23 | 2021-02-09 | Pfizer Inc. | specific antibodies to gucy2c and uses thereof |
AU2019299439A1 (en) | 2018-07-03 | 2021-01-21 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
SG11202101994XA (en) | 2018-08-28 | 2021-03-30 | Vor Biopharma Inc | Genetically engineered hematopoietic stem cells and uses thereof |
ES2967696T3 (en) | 2019-04-08 | 2024-05-03 | Giuseppe Scalabrino | Epidermal growth factor (EGF) and variants thereof for treating or preventing inflammatory demyelinating disorders |
US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
US20210005283A1 (en) | 2019-07-03 | 2021-01-07 | Bostongene Corporation | Techniques for bias correction in sequence data |
EP4041308A1 (en) | 2019-10-07 | 2022-08-17 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
JP2022553640A (en) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | Methods of treating eye disorders |
WO2021072244A1 (en) | 2019-10-11 | 2021-04-15 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
EP4093426A1 (en) | 2020-01-24 | 2022-11-30 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
WO2021224850A1 (en) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
MX2023000662A (en) | 2020-07-17 | 2023-02-27 | Pfizer | Therapeutic antibodies and their uses. |
EP4189093A1 (en) | 2020-07-30 | 2023-06-07 | Pfizer Inc. | Cells having gene duplications and uses thereof |
EP4343004A2 (en) | 2020-10-19 | 2024-03-27 | Dana-Farber Cancer Institute, Inc. | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
US20240024474A1 (en) | 2020-11-13 | 2024-01-25 | David Avigan | Personalized fusion cell vaccines |
US20220180972A1 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
WO2022159793A2 (en) | 2021-01-25 | 2022-07-28 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for identifying neuroendocrine prostate cancer |
WO2022232615A1 (en) | 2021-04-29 | 2022-11-03 | Bostongene Corporation | Machine learning techniques for estimating tumor cell expression complex tumor tissue |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
CA3227875A1 (en) | 2021-08-02 | 2023-02-09 | Pfizer Inc. | Improved expression vectors and uses thereof |
IL311712A (en) | 2021-09-27 | 2024-05-01 | Sotio Biotech Inc | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
IL312540A (en) | 2021-11-16 | 2024-07-01 | Sotio Biotech Inc | Treatment of myxoid/round cell liposarcoma patients |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
WO2023147177A1 (en) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Machine learning techniques for cytometry |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
WO2023158732A1 (en) | 2022-02-16 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof |
WO2024015561A1 (en) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques for detecting homologous recombination deficiency (hrd) |
WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
WO1993022433A2 (en) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
-
1993
- 1993-06-03 JP JP6501565A patent/JPH07507689A/en active Pending
- 1993-06-03 WO PCT/US1993/005260 patent/WO1993025234A1/en not_active Application Discontinuation
- 1993-06-03 EP EP93914334A patent/EP0650370A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
WO1993022433A2 (en) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
Non-Patent Citations (8)
Title |
---|
ADV. EXP. MED. BIOL. (1988), 241(MOL. BIOL. HEMOPOIESIS), 19-27 CODEN: AEMBAP;ISSN: 0065-2598 * |
CHEMICAL ABSTRACTS, vol. 111, no. 13, 25 September 1989, Columbus, Ohio, US; abstract no. 110248, EGLITIS, MARTIN A. ET AL: "Retroviral-mediated gene transfer into hemopoietic cells" * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; * |
KASAHARA N. ET AL.: "TARGETED GENE DELIVERY BY RETROVIRUSES WITH PEPTIDE HORMONE SEQUENCES INCORPORATED INTO THE ENVELOPE.", J. CELL BIOCHEM. SUPPL., vol. 0, pages 237 * |
LI, JING PO ET AL: "Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor", NATURE (LONDON) (1990), 343(6260), 762-4 CODEN: NATUAS;ISSN: 0028-0836 * |
RANDY A. HOCK ET AL.: "RETROVIRUS-MEDIATED TRANSFER AND EXPRESSION OF DRUG RESISTANCE GENES IN HUMAN HAEMATOPOIETIC PROGENITOR CELLS.", NATURE, vol. 320, 20 March 1986 (1986-03-20), LONDON GB, pages 275 - 277 * |
See also references of WO9325234A1 * |
YOSHIMURA, AKIHIKO ET AL: "Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism", PROC. NATL. ACAD. SCI. U. S. A. (1990), 87(11), 4139-43 CODEN: PNASA6;ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
EP0650370A1 (en) | 1995-05-03 |
WO1993025234A1 (en) | 1993-12-23 |
JPH07507689A (en) | 1995-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0650370A4 (en) | Methods and compositions for targeting specific tissue. | |
PH31081A (en) | Methods and compositions for mineralizing and fluoridating calcified tissues. | |
EP0634459A3 (en) | Formulations. | |
ZA932646B (en) | Cosmetic composition. | |
ZA936704B (en) | Cosmetic composition. | |
ZA945653B (en) | Therapeutic compositions | |
EP0640097A4 (en) | Compositions and methods for vaccination against coronaviruses. | |
EP0604748A3 (en) | Trocar sleeve. | |
ZA932586B (en) | Cosmetic composition. | |
GB2271059B (en) | Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives. | |
ZA942814B (en) | Agricultural formulations | |
EP0596962A4 (en) | Therapeutic compositions and methods. | |
PH31211A (en) | Cosmetic composition. | |
EP0656791A4 (en) | Therapeutic compositions and methods using pqq. | |
HK1001286A1 (en) | Benzopyrans and their use as therapeutic agents. | |
GB2294213B (en) | Pulverizer | |
ZA966063B (en) | Synergistic herbicidal composition and method of use thereof. | |
AU3674595A (en) | Antianemic agent containing iron and difructose | |
AU663832B2 (en) | Easy chess-like game | |
EP0586848A3 (en) | Implant. | |
EP0868430A4 (en) | Therapeutic compositions | |
EP0673640A4 (en) | Intermediate permanent wave treatment composition. | |
AU3423397A (en) | Therapeutic methods and compositions for use therein | |
ZA93662B (en) | Sterilising composition | |
PL303352A1 (en) | Symmetrical plough |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941124 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19951006 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 39/12 |
|
17Q | First examination report despatched |
Effective date: 19980605 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19991125 |